Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
-5.8% vs SMA 50 · +7.2% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2024 | $132.8B $132.3B–$133.7B | — | $71.97 | — | ±1% | High19 |
FY2025 | $129.0B $127.7B–$129.7B | ▼ -2.8% | $54.30 | ▼ -24.6% | ±12% | High24 |
FY2026(current) | $133.3B $131.0B–$138.8B | ▲ +3.3% | $54.23 | ▼ -0.1% | ±13% | High25 |
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease…

baidu was founded in 2000 by internet pioneer robin li, creator of visionary search technology hyperlink analysis, with the mission of providing people with the best way to find information and connect users with services. over the past decade we have strived to fulfill this mission by listening carefully to our users’ needs and wants. to provide intelligent, relevant search results for the tens of billions of queries that are entered into our search platform every day, we focus on powering the best technology optimized for up-to-date local tastes and preferences. our deep understanding of chinese language and culture is central to our success and this kind of knowledge allows us to tailor our search technology for our users’ needs. we provide our users with many channels to find and share information. in addition to our core web search product, we power many popular community-based products, such as baidu postbar, the world’s first and largest chinese-language query-based searchable o